Makary pointed to three bottlenecks: hospital contracting; ethical reviews and approvals; and the Investigational New Drug ...

Feb 18 (Reuters) - Contract drug developer Charles River Laboratories on Wednesday forecast annual profit above Wall Street estimates, betting on an improvement in demand for its drug discovery and ...

Unnatural Products is proving to be a natural at securing partnerships, this time linking up with Novartis in a deal that could garner up to $1.7 billion in biobucks.

BOSTON, Nov. 06, 2025 (GLOBE NEWSWIRE) -- BPGbio, Inc., a biology-first, AI-powered, clinical-stage biopharma focused on mitochondrial biology and protein homeostasis, today announced it has won the ...

Four drug companies — Agomab Therapeutics, Eikon Therapeutics, Spyglass Pharma, and Veradermics — went public this week, ...

Axol Bioscience Ltd. (Axol), a leading provider of induced pluripotent stem cell (iPSC) technologies for drug discovery and ...

The pharmaceutical industry is experiencing its own “DeepSeek moment,” according to science writer Hiya Jain. Just as the upstart AI breakthrough caught Silicon Valley off-guard, China is emerging as ...

Chinese pharmaceutical companies that as a group chalked up record outbound licensing agreements with international industry giants last year are poised to make further advances in 2026, the chairman ...

EIR Biopharma is hoping to bring in $17.1 million from an IPO on the New York Stock Exchange that could fund development of its preclinical eye disease drug. | EIR Biopharma is hoping to bring in $17.

And there's more than one way to monetize this technology.

AI boosts efficiency in early, high-failure R&D, improving success rates and capital efficiency across biotech and pharma.